Business news for the stock market
Leverkusen, Germany (pta023/05.07.2023/11:25) - Biofrontera (ISIN: DE0006046113) announces that the active cosmetic series belixos® has been extended by the care foam belixos® ACTIVE CARE.
belixos® ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin that can be used as basic care for atopic dermatitis and psoriasis, as well as for soothing intensive care for everyday skin problems. With its innovative formulation as a foam, it provides a pleasant feeling on the skin without a greasy film and enables particularly gentle application of the high-quality ingredients as a result of the reduced foam formulation.
Due to it ` s innovative nature, Biofrontera was able to register the underlying innovative foam formulation as a patent.
As previously in the belixos® cosmetics series, the focus is on the traditional medicinal plant Mahonia as an active component. The medicinal plant, which is still quite unknown in European country but has been used for centuries in the medicine of the indigenous peoples of North America, is known to have anti-inflammatory, antipruritic and antiseptic properties.
With the help of Biofrontera's proprietary biocolloid technology, the plant-based active ingredients penetrate very quickly into the epidermis and distribute there in order to unfold their soothing and regenerating effect in this very sensitive layer of skin that is particularly accessible to external influences.
"With this state-of-the-art product Biofrontera strengthens its position as an innovative company in the dermatological field. With the launch of belixos® ACTIVE CARE we expand our scope in dermatology by additionally providing a basic care for irritated and itchy skin. We will mainly promote it to dermatologists so Biofrontera could enhance our position as a key partner and expert in dermatology", Pilar de la Huerta, CFO of Biofrontera comments the launch.
belixos® ACTIVE CARE will be available in Germany in two product sizes at pharmacies and via the online retailer Amazon, as a 35ml-can at EUR 19.95 RRP and as a 100ml-can at EUR 29.95 RRP.
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (Prime Standard). www.biofrontera.com
Forward-looking statements: This release contains certain forward-looking statements. These reflect the views of Biofrontera as of the date of this communication. Actual results achieved by Biofrontera may differ materially from those set forth in the forward-looking statements. Biofrontera is under no obligation to update forward-looking statements.
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate